SeaStar Medical (ICU) estimates a U.S. total addressable market for its proprietary, patented Selective Cytopheretic Device in five clinical indications, subject to U.S. FDA approvals, of $25B-$33B.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICU:
- SeaStar Medical announces activation of Sentara Norfolk General as active site
- SeaStar announces two advisory firms recommended vote favor of proposals
- SeaStar Medical reaches milestone of 100th QUELIMMUNE commercial device
- Seastar Medical Faces Distribution Challenges with Self-Marketing of QUELIMMUNE
- ICU Earnings Report this Week: Is It a Buy, Ahead of Earnings?